DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» EZH2
EZH2
Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Histone Methylases As Novel Drug Targets. Focus on EZH2 Inhibition. Catherine BAUGE1,2,#, Céline BAZILLE 1,2,3, Nicolas GIRARD1
Histone Deacetylase Inhibitors Synergizes with Catalytic Inhibitors of EZH2 to Exhibit Anti-Tumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
EZH2 in Normal Hematopoiesis and Hematological Malignancies
TAZVERIK (Tazemetostat) RATIONALE for INCLUSION in PA PROGRAM
Regulation of Histone Methylation by Automethylation of PRC2
Mutations in Epigenetic Regulators Including SETD2 Are Gained During Relapse in Paediatric Acute Lymphoblastic Leukaemia
Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: a Century-Long Story
The Role of ATP-Dependent Chromatin Remodeling Enzyme CHD7 in the Development and Maintenance of Murine Neural Stem Cells By
PRC2 Directly Methylates GATA4 and Represses Its Transcriptional Activity
And BBAP- Mediated DNA Repair to Overcome Chemoresistance in EZH2 Gain-Of-Function Mutant Diffuse Large B-Cell Lymphoma
JARID2 and AEBP2 Regulate PRC2 Activity in the Presence of H2A Ubiquitination Or Other Histone Modifications
The N-Terminal Methyltransferase Homologs NRMT1 and NRMT2 Exhibit Novel Regulation of Activity Through Heterotrimer Formation
Metabolic Control of Histone Methylation and Gene Expression in Cancer Thai Q
Jarid2 Is a PRC2 Component in Embryonic Stem Cells Required for Multi-Lineage Differentiation and Recruitment of PRC1 and RNA Po
Differential Gene Expression in Scrub Typhus Compared to Other Acute Febrile Infections by Bioinformatic Approaches
Inhibition of EZH2 Prevents Fibrosis and Restores Normal Angiogenesis in Scleroderma
Top View
A Partially Disordered Region Connects Gene Repression and Activation Functions of EZH2
O-Glcnacylation Regulates EZH2 Protein Stability and Function
DNA Methylation Targeting: the DNMT/HMT Crosstalk Challenge
Medicaid Health Plan Common Formulary
Histone H3K27 Methyltransferase Ezh2 Represses Wnt Genes to Facilitate Adipogenesis
Differentiation Potential of Pluripotent Stem Cells Correlates to the Level Of
Abstract Hypothesis References Acknowledgements EZH2 Expression Is Decreased with Inhibition of Hmof Pmypt1 Expression Is Decrea
277 P057 the Discovery and Pre-Clinical Development of the First Clinical Stage EZH2-Inhibitor, EPZ-6438 (E7438)
Investigation of Chd7 Function in Developmental Models Of
Epigenetic Effects of Endocrine Disrupting Chemicals
A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Ezh2-Dcas9 and KRAB-Dcas9 Enable Engineering of Epigenetic Memory in a Context-Dependent Manner
MYC-Driven Small-Cell Lung Cancer Is Metabolically Distinct and Vulnerable to Arginine Depletion Milind D
Targeting EZH2 Histone Methyltransferase Activity Alleviates Experimental Intestinal Inflammation
Supplementary Appendix
Post-Translational Modifications of EZH2 in Cancer
Mutation of A677 in Histone Methyltransferase EZH2 in Human B-Cell Lymphoma Promotes Hypertrimethylation of Histone H3 on Lysine 27 (H3K27)
S13568-020-01076-6.Pdf
Histone Deacetylase Inhibitors Deplete Enhancer of Zeste 2 and Associated Polycomb Repressive Complex 2 Proteins in Human Acute Leukemia Cells
Nucleosome-Binding Activities Within JARID2 and EZH1 Regulate the Function of PRC2 on Chromatin
Epigenetic Regulation of Cancer Progression by EZH2: from Biological Insights to Therapeutic Potential
Ezh2 Antibody A
EZH2 Gene Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit
Phosphorylation of the PRC2 Component Ezh2 Is Cell Cycle-Regulated and Up-Regulates Its Binding to Ncrna
Chemical Genomics Reveals Histone Deacetylases Are Required for Core Regulatory Transcription
CHD7 Targets Active Gene Enhancer Elements to Modulate ES Cell-Specific Gene Expression
Genomic Analysis of Ribosomal Dna and Its Application to The
Enhancer of Zeste Homolog 2 (EZH2) Mediates Glucolipotoxicity-Induced Apoptosis in Β-Cells
Dietary Components As Epigenetic-Regulating Agents Against Cancer
Epigenetic Biomarkers for Clinical Outcomes and Mechanisms Driving Emergence of Drug Resistance in Ovarian Cancer
Methyltransferase Inhibitors: Competing With, Or Exploiting the Bound Cofactor
Selective Inhibition of Ezh2 by a Small Molecule Inhibitor Blocks Tumor Cells Proliferation
Histone H3 Tail Binds a Unique Sensing Pocket in EZH2 to Activate the PRC2 Methyltransferase
The Role of Non-Coding Rnas in the Regulation of the Proto-Oncogene MYC in Different Types of Cancer
Nascent RNA Interaction Keeps PRC2 Activity Poised and in Check
PRC2 Is Required to Maintain Expression of the Maternal Gtl2
Mechanistic Enzymology in Drug Discovery: a Fresh Perspective
Growth Inhibition and Transcriptional Effects of Ribavirin in Lymphoma
Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas Jennifer K
Transition State for the NSD2-Catalyzed Methylation of Histone H3 Lysine 36
Quantitative Proteomics Identifies Vasopressin- Responsive Nuclear Proteins in the Collecting Duct”
The Roles of the Histone Protein Modifier EZH2 in the Uterus and Placenta
No Easy Way out for EZH2: Its Pleiotropic, Noncanonical Effects on Gene Regulation and Cellular Function
EZH2: Not EZHY (Easy) to Deal